Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 1:30 p.m. ET.
A live webcast and 90-day replay will be available via Verrica’s investor relations website.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported Q1 2026 revenue of $5.0 million, including U.S. YCANTH net product revenue of $4.3 million, up 16.2% sequentially and 25.4% year-over-year. Dispensed YCANTH applicator units reached 15,302, up 12.1% sequentially and 51.3% year-over-year.
YCANTH surpassed 100,000 total dispensed units since launch and was commercially launched in Japan by partner Torii. Verrica reported a GAAP net loss of $9.7 million and continues Phase 3 programs in common warts and development of VP-315 for basal cell carcinoma.
Verrica Pharmaceuticals (Nasdaq: VRCA) will present Phase 2 data on VP-315 (ruxotemitide) showing reductions in untreated basal cell carcinoma (BCC) lesions consistent with a potential abscopal effect. In 9 subjects, 14 non-treated lesions showed a 67% overall size reduction and 21% complete histologic clearance (3/14).
The poster will be presented May 15, 2026 at the SID Annual Meeting and reports an average 86% overall tumor-size reduction referenced for treated patients.
Verrica Pharmaceuticals (Nasdaq: VRCA) will report first-quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026 at 4:30 p.m. ET.
The company will host a conference call and live webcast; domestic and international dial-in numbers and a conference ID (VERRICA) are provided. A webcast replay will be archived on Verrica's investor website for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data for VP-315, its oncolytic peptide for basal cell carcinoma, showing a potential abscopal effect in untreated non-target BCC tumors.
The data will be presented at the 2026 Society for Investigative Dermatology Annual Meeting, May 13-16, with the poster session on May 15, 2026 (4:30 pm–6:00 pm) in Chicago (Hilton Chicago, Salons B,C,D).
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00pm ET.
A live webcast will be available via Verrica's investor site and a replay will be posted and available for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported full-year 2025 results and operational updates on March 11, 2026. YCANTH net revenue grew 130% to $15.3M and dispensed applicator units rose 99% to 51,296. Total 2025 revenue was $35.6M vs. $7.6M in 2024.
The company cut SG&A by over 40%, has no outstanding debt after a $50M private placement, and expects cash runway into Q1 2027. Clinical progress: first patient dosed in Phase 3 common warts program and VP-315 advances toward Phase 3 for basal cell carcinoma with supportive abscopal data.
Verrica Pharmaceuticals (Nasdaq: VRCA) will report fourth quarter and full year 2025 financial results and provide a corporate update on March 11, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET; dial-in details, conference ID VERRICA, and a 90-day webcast replay are available on the company website.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Jayson Rieger will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026 at 10:30am ET.
According to the company, a live webcast will be available on Verrica's investor website and a replay will be posted and available for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA) appointed Chris Chapman as Chief Commercial Officer effective Feb 12, 2026. Chapman brings over 25 years of commercial pharmaceutical experience and leadership across dermatology, including roles at Dermavant, Organon, Galderma, and Pfizer.
Management expects Chapman to expand U.S. commercial capabilities for YCANTH, support the global Phase 3 program for common warts, and advance development of VP-315 for basal cell carcinoma.